Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone.
OBJECTIVE
To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS).


METHODS
Case report.


METHODS
Academic clinical practice and General Clinical Research Center.


METHODS
A 25-year-old woman with PCOS.


METHODS
Rosiglitazone maleate, 4 mg daily for 5 months until conception.


METHODS
Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images.


RESULTS
Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception.


CONCLUSIONS
Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted.
Cataldo
N A
NA
Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Stanford University Medical Center, California 94305-5317, USA. ncataldo@stanford.edu
Abbasi
F
F
McLaughlin
T L
TL
Lamendola
C
C
Reaven
G M
GM
D000328:Adult; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000502:physiology*; D010060:Ovulation; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D011247:Pregnancy; D000077154:Rosiglitazone; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones
D007004:Hypoglycemic Agents; D007328:Insulin; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone